Related Experiment Video

Updated: May 11, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

A new mode of RAF autoregulation: a further complication in the inhibitor paradox

Fiona Hey1, Catrin Pritchard

  • 1Department of Biochemistry, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK.

Cancer Cell
|May 18, 2013
PubMed

Insights

RAF inhibitors effectively treat BRAF(V600E) melanoma but paradoxically activate ERK in wild-type BRAF cells. This study reveals RAF autoinhibition as the mechanism, complicating RAF-targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • BRAF inhibitors yield impressive responses in BRAF(V600E) melanoma.
  • ERK pathway activation in wild-type BRAF cells is a known adverse effect of RAF inhibitors.
  • This paradoxical activation complicates treatment strategies.

Purpose of the Study:

  • To elucidate the mechanism behind ERK pathway activation in wild-type BRAF cells treated with RAF inhibitors.
  • To understand the role of RAF autoinhibition in this paradoxical response.
  • To inform future therapeutic strategies targeting RAF.

Main Methods:

  • Investigated RAF autoinhibition in cells expressing wild-type BRAF.
  • Analyzed the impact of RAF inhibitors on ERK pathway signaling.
  • Utilized cellular and molecular biology techniques.

Main Results:

  • RAF autoinhibition was identified as the underlying mechanism for paradoxical ERK activation.
  • This autoinhibition complicates the efficacy of RAF-targeted therapies.
  • Demonstrated a direct link between RAF autoinhibition and adverse ERK signaling.

Conclusions:

  • RAF autoinhibition is a key factor in the paradoxical ERK activation observed with RAF inhibitors.
  • Understanding this mechanism is crucial for developing more effective and safer RAF-targeted cancer therapies.
  • This finding presents new challenges and opportunities for melanoma treatment.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Assessing Cerebral Autoregulation via Oscillatory Lower Body Negative Pressure and Projection Pursuit Regression11:26

Assessing Cerebral Autoregulation via Oscillatory Lower Body Negative Pressure and Projection Pursuit Regression

Published on: December 10, 2014

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...